# A Study of RAY1225 in Participants With Impaired Liver Function

> **NCT06577415** · PHASE1 · RECRUITING · sponsor: **Guangdong Raynovent Biotech Co., Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** RAY1225

## Key facts

- **NCT ID:** NCT06577415
- **Lead sponsor:** Guangdong Raynovent Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-26
- **Primary completion:** 2025-10-31
- **Final completion:** 2025-11-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2025-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06577415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06577415, "A Study of RAY1225 in Participants With Impaired Liver Function". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT06577415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*